In vitro inhibition of gene transcription by novel photo-activated polyazaaromatic ruthenium(II) complexesElectronic supplementary information (ESI) available: representatve autoradiograph for the transcribed messenger RNA of expected size and experimental procedures. See http://www.rsc.org/suppdata/cc/b2/b202905g/Abbreviations: POQ-Nmet: 5-{4-[N-methyl-N-(7-chloroquinolin-4-yl)amino]-2-thiabutanecarboxamido}-1,10-phenanthroline; TAP: 1,4,5,8-tetraazaphenanthrene; HAT: 1,4,5,8,9,12-hexaazatriphenylene

Pauly, Marc; Kayser, I.; Schmitz, M. Lienhard; Dicato, Mario-Antonio; Guerzo, André Del; Kolber, Isabelle; Moucheron, Cécile; Mesmaeker, Andrée Kirsch‐De

doi:10.1039/b202905g

Cited by 30 publications

(20 citation statements)

References 17 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…69 Compounds capable of photo-reacting with DNA may also have dramatic effects on DNA functions and gene expression, and therefore are potential anticancer drug candidates. 70 Conjugates of PDT photosensitizers, such as porphyrins, with classical platinum chemotherapeutics, i.e. Pt(II) compounds structurally similar to cisplatin and carboplatin, have been investigated with the aim of combining in one molecule the phototoxicity with more conventional DNA damage for the treatment of cancer.…”

Section: Photoactive Metal Compoundsmentioning

confidence: 99%

A categorization of metal anticancer compounds based on their mode of action

2009

View full text Add to dashboard Cite

The development of new metal anticancer compounds is a challenge for inorganic chemists. We have to face the fact that four decades of research in this field have only produced a small number of clinically used compounds, most often developed through serendipity rather than through rational chemical design. Nevertheless, by virtue of the wealth of knowledge acquired in these years, medicinal inorganic chemistry is probably mature for making significant steps forward and there are great expectations for future developments. With the aim of contributing to the rationalization of this field, we suggest here a categorization of metal anticancer compounds into five classes based on their mode of action: (i) the metal has a functional role, i.e. it must bind to the biological target; (ii) the metal has a structural role, i.e. it is instrumental in determining the shape of the compound and binding to the biological target occurs through non-covalent interactions; (iii) the metal is a carrier for active ligands that are delivered in vivo; (iv) the metal compound is a catalyst; and (v) the metal compound is photoactive and behaves as a photo-sensitizer. Selected examples for each category are given. The few metal anticancer drugs that are in clinical use are all believed to be functional compounds. Our classification, that is clearly focused on the metal compound and is independent from the nature of its bio-target(s)-most often still unknown-has the purpose of providing an intellectual tool that might be helpful in the rational development of new drugs.

show abstract

Section: Photoactive Metal Compoundsmentioning

confidence: 99%

A categorization of metal anticancer compounds based on their mode of action

2009

View full text Add to dashboard Cite

show abstract

“…The DNA photodamage caused by these complexes could be exploited for biomedical applications. For example Ru II -TAP complexes reduce the in vitro transcription rate of a plasmid DNA by a bacteriophage RNA polymerase to 50% whereas the complex is inactive in the dark [101].…”

Section: Mono-adduct Formationmentioning

confidence: 99%

Photo-oxidizing RuII complexes and light: Targeting biomolecules via photoadditions

Marcélis

Ghesquière

Garnir

et al. 2012

Coordination Chemistry Reviews

Self Cite

View full text Add to dashboard Cite

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues. Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited. In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

show abstract

“…In fact, they are able to produce, upon illumination, addition of the metal-containing complex to the guanine units of DNA, which inhibits certain enzymes such as RNA polymerase. [12] They could thus offer different advantages: i) their action would be triggered exclusively under illumination, a better control of the activity could thus be expected, ii) the type of their photoadducts is quite different from known metal-containing adducts; indeed contrary to the Pt complexes, their coordination sphere around the metal is kept unchanged after the photoadduct formation. The consequences at the level of the activity or effect of such photoadducts on the cellular function could thus be different and open the way to potential novel drugs.…”

Section: Introductionmentioning

confidence: 99%

Photoreaction of [Ru(hat)₂phen]²⁺ with Guanosine‐5′‐Monophosphate and DNA: Formation of New Types of Photoadducts

Blasius

Nierengarten²,

Luhmer

et al. 2005

Chemistry A European J

View full text Add to dashboard Cite

[Ru(hat)2phen]2+ (HAT=1,4,5,8,9,12-hexaazatriphenylene, phen=1,10-phenanthroline) interacts with a good affinity with polynucleotides and DNA by intercalation, despite the presence of a second voluminous ancillary HAT ligand. It photoreacts with guanosine-5'-monophosphate (GMP). From HPLC, ESMS and NMR analyses, it can be concluded that this complex forms photoadducts with GMP. In contrast to the photoadducts isolated with Ru-TAP complexes (TAP=1,4,5,8-tetraazaphenanthrene), the photoadducts with [Ru(hat)2phen]2+ contain a covalent link between the oxygen atom of the guanine unit and a HAT ligand. Formation of oxidised photoadducts and compounds resulting from the addition of two GMP entities to the complex are also detected as side products. In the presence of oligo- and polynucleotides, [Ru(hat)2phen]2+ yields photoadducts when guanine bases are present.

show abstract

Cited by 30 publications

References 17 publications

A categorization of metal anticancer compounds based on their mode of action

A categorization of metal anticancer compounds based on their mode of action

Photo-oxidizing RuII complexes and light: Targeting biomolecules via photoadditions

Photoreaction of [Ru(hat)₂phen]²⁺ with Guanosine‐5′‐Monophosphate and DNA: Formation of New Types of Photoadducts

Contact Info

Product

Resources

About

Cited by 30 publications

References 17 publications

A categorization of metal anticancer compounds based on their mode of action

A categorization of metal anticancer compounds based on their mode of action

Photo-oxidizing RuII complexes and light: Targeting biomolecules via photoadditions

Photoreaction of [Ru(hat)2phen]2+ with Guanosine‐5′‐Monophosphate and DNA: Formation of New Types of Photoadducts

Contact Info

Product

Resources

About

Photoreaction of [Ru(hat)₂phen]²⁺ with Guanosine‐5′‐Monophosphate and DNA: Formation of New Types of Photoadducts